Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1227)	10/8/2002 7:32:34 PM
From: tuck	Read Replies (1) \| Respond to of 1784

My perception is that real estate is a bit bubbly, and that this amounts to ARE buying at the top. So Trickle sure hopes it got a good deal; the market didn't seem to think so today. BDAL, still coping with a large (though dwindling) short position, crows as it often does about its order bookings. So they'd better hit their earnings numbers. >>BILLERICA, Mass.--(BUSINESS WIRE)--Oct. 7, 2002--Bruker Daltonics Inc. (Nasdaq:BDAL - News) today reported that new order bookings for its life-science systems grew 22% in the third quarter of 2002, compared to Q3-2001. Frank Laukien, President and Chief Executive Officer, commented: "In the third quarter, we were pleased with the continued excellent acceptance of our UltraFlex TOF/TOF system by new and repeat customers. During the quarter, we received an order for more than ten UltraFlex TOF/TOF systems from a European pharmaceutical company. We can also report a large order from a research hospital in Asia for a complete Proteineer solution, including our spot picking robot, our digest and prep robot, a MALDI-TOF/TOF, an ion trap, and our ProteinScape integrated proteomics software, for over one million dollars." "Our direct ion trap mass spectrometry sales are growing nicely and our new ESI-TOF and ESI-Q-q-TOF product family is experiencing dramatic growth, albeit from a small basis. Last but not least, we have now received initial orders for our new high-field 9.4 and 12 Tesla FTMS systems optimized for ultra-high resolution proteomics analysis."<< snip Overdue for a disclosure update. The manager owns a bit of BDAL and rather more QGENF. Cheers, Tuck